Clinical perspectives for ghrelin-derived therapeutic products

Endocrine Development

Volumn 25, Issue , 2013, Pages 157-166

  Allas, Soraya ^a   Abribat, Thierry ^a  

^a Alizé Pharma ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLATED GHRELIN BLOCKING AGENT; ACYLTRANSFERASE; AZP 531; GHRELIN; GHRELIN O ACYLTRANSFERASE; GHRELIN O ACYLTRANSFERASE INHIBITOR; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE RECEPTOR 1A ANTAGONIST; HORMONE DERIVATIVE; HORMONE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ACYLATION; ARTICLE; DRUG POTENCY; ENZYME MECHANISM; GLUCOSE METABOLISM; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL;

EID: 84877941277     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000346065     Document Type: Article

References (27)

1. Merriam GR, Blackman M, Hoffman A, Salvatori R, Wei JY, White HK, et al: Effects of chronic treatment with an oral growth hormone (GH) secretagogue on nocturnal GH and insulin-like growth factor-I (IGFI) in older men and women. Front Neuroendocrinol 2006; 27: 36-37.
2. Greenwood-Van MB, Kriegsman M, Nelson R: Ghrelin as a target for gastrointestinal motility disorders. Peptides 2011; 32: 2352-2356.
3. Beck B, Richy S, Stricker-Krongrad A: Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci 2004; 76: 473-478.
4. Maletinska L, Matyskova R, Maixnerova J, Sykora D, Pychova M, Spolcova A, et al: The Peptidic GHS-R antagonist [ D -Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Mol Cell Endocrinol 2011; 343: 55-62.
5. Esler WP, Rudolph J, Claus TH, Tang W, Barucci N, Brown SE, et al: Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology 2007; 148: 5175-5185.
6. Roy MC, Paradis E, Samson P, Thiboutot-Gagnon N, Marcotte M, Lachance Y, et al: Long term treatment with non-peptide ghrelin receptor ligands affects energy balance in mice fed a high-fat diet. ENDO 2007: 2-9.
7. Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D, et al: Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci USA 2009; 106: 11318-11323.
8. Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid A, et al: Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol 2004; 151(suppl 1):S71-S75.
9. Costantini VJ, Vicentini E, Sabbatini FM, Valerio E, Lepore S, Tessari M, et al: GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 2011; 94: 158-168.
10. Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW: High constitutive signaling of the ghrelin receptor - identification of a potent inverse agonist. Mol Endocrinol 2003; 17: 2201-2210.
11. Kobelt P, Helmling S, Stengel A, Wlotzka B, Andresen V, Klapp BF, et al: Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut 2006; 55: 788-792.
12. Shearman LP, Wang SP, Helmling S, Stribling DS, Mazur P, Ge L, et al: Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 2006; 147: 1517-1526.
13. Becskei C, Bilik KU, Klussmann S, Jarosch F, Lutz TA, Riediger T: The anti-ghrelin Spiegelmer NOXB11-3 blocks ghrelin- but not fasting-induced neuronal activation in the hypothalamic arcuate nucleus. J Neuroendocrinol 2008; 20: 85-92.
14. Lu SC, Xu J, Chinookoswong N, Liu S, Steavenson S, Gegg C, et al: An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. Mol Pharmacol 2009; 75: 901-907.
15. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, et al: Vaccination against weight gain. Proc Natl Acad Sci USA 2006; 103: 13226-13231.
16. Barnett BP, Hwang Y, Taylor MS, Kirchner H, Pfluger PT, Bernard V, et al: Glucose and weight control in mice with a designed ghrelin O -acyltransferase inhibitor. Science 2010; 330: 1689-1692.
17. Granata R, Settanni F, Biancone L, Trovato L, Nano R, Bertuzzi F, et al: Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: involvement of 3 ' ,5 ' -cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling. Endocrinology 2007; 148: 512-529.
18. Granata R, Volante M, Settanni F, Gauna C, Ghe C, Annunziata M, et al: Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol 2010; 45: 9-17.
19. Granata R, Settanni F, Julien M, Nano R, Togliatto G, Trombetta A, et al: Unacylated ghrelin fragments and analogues promote survival of pancreatic betacells and human pancreatic islets and prevent diabetes in streptozotocin-treated rats. J Med Chem 2012; 55: 2585-2596.
20. Delhanty PJ, Huisman M, Baldeon-Rojas LY, van den Berge I, Grefhorst A, Abribat T, Leenen PJ, Themmen AP, van der Lely AJ: Des-acyl ghrelin analogs prevent high-fat-dietinduced dysregulation of glucose homeostasis. FASEB J 2013;in press.
21. Julien M, Kay R, Delhanty P, Allas S, Granata R, Barton C, et al: In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues. Eur J Pharm Sci 2012; 47: 625-635.
22. Özcan B, Neggers SJCMM, Miller AR, Yang H, Delhanty P, Allas S, et al: Rapidly and strong suppression of human acylated ghrelin serum concentrations during infusion of des-acyl ghrelin in obese diabetic subjects. Endocr Abstr 2012; 29: 711.
23. Togliatto G, Trombetta A, Dentelli P, Baragli A, Rosso A, Granata R, et al: Unacylated ghrelin rescues endothelial progenitor cell function in individuals with type 2 diabetes. Diabetes 2010; 59: 1016-1025.
24. Baldanzi G, Filigheddu N, Cutrupi S, Catapano F, Bonissoni S, Fubini A, et al: Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/ AKT. J Cell Biol 2002; 159: 1029-1037.
25. Lear PV, Iglesias MJ, Feijoo-Bandin S, Rodriguez-Penas D, Mosquera-Leal A, Garcia-Rua V, et al: Desacyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes. Endocrinology 2010; 151: 3286-3298.
26. Filigheddu N, Gnocchi VF, Coscia M, Cappelli M, Porporato PE, Taulli R, et al: Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell 2007; 18: 986-994.
27. Sheriff S, Kadeer N, Joshi R, Friend LA, Howard JJ, Balasubramaniam A: Des-acyl ghrelin exhibits proanabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats. Mol Cell Endocrinol 2012; 351: 286-295.